A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

9.1K views

⸱

DOI:

10.3791/58140

⸱

October 3rd, 2018

 ,  ,  , 

In This Article

Summary

We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.

Abstract

Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic stem cell disorders that are defined by ineffective hematopoiesis, peripheral blood cytopenias, dysplasia, and a propensity for transformation to acute leukemia. NUP98-HOXD13 (NHD13) transgenic mice recapitulate human MDS in terms of peripheral blood cytopenias, dysplasia, and transformation to acute leukemia. We previously demonstrated that MDS could be transferred from a genetically engineered mouse with MDS to wild-type recipients by transplanting MDS bone marrow nucleated cells (BMNC). To more clearly understand the MDS cell of origin, we have developed approaches to transplant specific, immunophenotypically defined hematopoietic subsets. In this article, we describe the process of isolating and transplanting specific populations of hematopoietic stem and progenitor cells. Following transplantation, we describe approaches to assess the efficiency of transplantation and persistence of the donor MDS cells.

Introduction

Myelodysplastic syndromes (MDS) represent a diverse set of clonal blood disorders characterized by ineffective hematopoiesis, morphologic evidence of dysplasia, and a propensity for transformation to acute myeloid leukemia (AML)1,2,3,4. Ineffective hematopoiesis is recognized as a maturation arrest in bone marrow, and results in peripheral blood cytopenias despite a hypercellular bone marrow1,3. The incidence of MDS has been variously estimated as 2-12 cases per 100,000 persons annua....

Access restricted. Please log in or start a trial to view this content.

Protocol

The animal procedures described in this article were approved by the National Cancer Institute at Bethesda Animal Care and Use Committee, and conform to the policies contained within The Public Health Service Policy on Humane Care and Use of Laboratory Animals, The Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals.

1. Cell Preparation

  1. Harvesting bone marrow nucleated cell (BMNC)
    1. Use only sterile materials. Sterilize re-usable instruments using a steam autoclave. Purchase needles, syringes, and plastic ware in single use sterile containers. Perform all animal and cell manipulations in a Clas....

Access restricted. Please log in or start a trial to view this content.

Results

We show representative figures for results of several experiments. Figure 1 shows a representative flow cytometry sorting experiment. During normal hematopoietic differentiation, as cells become committed to a specific hematopoietic lineage, they acquire lineage-defining cell surface markers and lose the potential for self-renewal. Therefore, in wild-type mice, stem cell self-renewal is confined to lineage-negative BMNC. In this experiment, we sorted BMNC fro.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Although MDS are a clonal hematopoietic stem cell disorder, the MDS "stem", or initiating cells, have not yet been characterized. We previously demonstrated that MDS can be transplantable to WT mice using bone marrow from NHD13 mice by HSCT, characterized by macrocytic anemia, leukopenia, neutropenia, and morphologic evidence of dysplasia15. In addition, competitive repopulation assays identified a growth advantage of cells from the NHD13 MDS bone marrow. Taken together, these findings imp.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

We have nothing to disclose.

Acknowledgements

This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health (grant numbers ZIA SC 010378 and BC 010983).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
14 mL round bottom tubeFalcon352057
Hank's balanced salt solutionLonza10-527F
Anti-CD45.2 antibodySouthern Biotech1800-15LOT# A077-T044O
3 mL SyringeMonoject8881513934
27-G needleBD305109
20-G needleBD305176
Lineage CocktailMiltenyi130-090-858LOT# 5170418221
Anti-Biotin antibodiesMiltenyi130-113-288LOT# 5171109046
1 mL SyringeExcelint26027Insulin Syringe
Heating LampThermo Fisher ScientificE70001901
FACS machineCytecFACScan2 lasers, 5 color detectors
FACS sorting instrumentBeckman CoulterMOFLO ASTRIOS5 lasers, 23 parameters, 6 population sorting simulteneously
Propidium IodideThermo Fisher ScientificP3566
Gamma IrradiatorBest TheratronicsGammacell 40
Blood collection tubeRAM scientific76011
Recipient miceCharles RiverB6-LY5.1/Cr, CD45.1
NUP98-HOXD13 micen/aC57Bl/6, CD45.2Colony maintained at NIH
5 mL round bottom tubeFalcon352058

References

  1. Corey, S. J., et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nature Reviews Cancer. 7 (2), 118-129 (2007).
  2. Garcia-Manero, G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification an....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Bone Marrow Nucleated CellsFlow CytometryTotal Body IrradiationCell SortingAdoptive TransferCD45.2 MarkerLineage Negative CellsPeripheral Blood Analysis